Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2020 June;68(3) > Minerva Cardioangiologica 2020 June;68(3):197-202

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Cardioangiologica 2020 June;68(3):197-202

DOI: 10.23736/S0026-4725.19.05026-6

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Prevention of diffuse, minimal lymphatic “retention” with Robuvit®: a concept, supplement registry study

Shuh HU, Gianni BELCARO , Morio HOSOI, Maria R. CESARONE, Valeria SCIPIONE, Claudia SCIPIONE, Mark DUGALL, Beatrice FERAGALLI, Roberto COTELLESE, Claudia MAIONE

IRVINE3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy



BACKGROUND: The aim of this study was to evaluate the effects of the standardized supplement Robuvit® (oak wood extract) in defined diffuse, minimal lymphatic “retention” (DMLR).
METHODS: Robuvit® has already been investigated in both primary and secondary (post-surgical, post chemo-radiotherapy) lymphatic insufficiency. This registry included subjects with diffuse, minimal lymphatic “retention” (DMLR). The registry management groups included women with mild-moderate limb swelling using standard management (SM) as controls. A second, comparable group used prevention with Robuvit® at the dosage of 3 cp/day (300 mg/day) for 4 weeks.
RESULTS: No tolerability problems or side effects were observed with the preventive supplementation. The management groups (34 women in total), including 18 women in Robuvit® and 16 in SM were comparable in age and baseline evaluations. After 4 weeks, in the Robuvit® group, edema scale values derived from ultrasound observations decreased significantly (P<0.05) at all measurement’s sites, from the proximal (inguinal) level to the more distal (ankle-foot) level. No significant changes in edema were observed in control subjects. Generally, in areas with higher level of edema (distal areas at the foot and ankle), the edema decrease was larger than in more proximal, ultrasound measurement sites.
CONCLUSIONS: Preventive Robuvit® supplementation appears to be safe and effective in controlling DMLR in subjects without significant or apparent clinical conditions. This preventive, concept study should be extended to a larger population for more meaningful observations.


KEY WORDS: Robuvit; Lymphatic diseases; Edema; Ultrasonography

inizio pagina